|
|
|
Exelixis Inc (NASDAQ: EXEL) |
|
|
|
| |
Exelixis Inc Outlook |
On January 13 2025 the Exelixis Inc provided following guidance
nnExelixis, Inc. Issues Preliminary Results for Fiscal Year 2024, Offers Outlook for 2025, and Highlights Strategic Priorities and Goals for the Upcoming Yearnn
nnALAMEDA, Calif.nn — Exelixis, Inc. (Nasdaq: EXEL) has released its preliminary unaudited financial results for the fiscal year 2024 and provided guidance for the upcoming fiscal year 2025, alongside a comprehensive update on its strategic business initiatives. The company is gearing up for a pivotal 2025, marked by significant clinical and regulatory advancements, particularly within its cabozantinib portfolio.
While specific financial projections for 2025 remain undisclosed, Exelixis emphasizes its commitment to driving growth through a robust pipeline of therapies, including multiple anticipated data releases for zanzalintinib. This year is positioned to be a transformative period, reflecting the company's dedication to advancing small molecules and biotherapeutics that aim to address critical unmet medical needs.
Exelixis has outlined its core objectives for 2025, which include enhancing the operational execution of ongoing clinical trials, fostering strategic partnerships, and further solidifying its presence in the oncology landscape. The company remains optimistic about the potential of its innovative therapies and is focused on leveraging its advancements to provide impactful treatment options for patients.
Through these initiatives, Exelixis aims to sustain its growth trajectory while delivering significant value to stakeholders and enhancing patient care in the oncology field. The company looks forward to sharing further specific financial metrics and updates as it progresses through 2025.,
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
